Discovery of a "First-in-Class" Selective Multikinase (CDK4/6/9-AURKA/B) Inhibitor, LCI133, for Neuroblastoma

Area of Science:

• Oncology
• Pharmacology
• Molecular Biology

Background:

• High-risk cancers often develop resistance to single-target therapies.
• Developing multi-target inhibitors offers a strategy to overcome therapeutic resistance.

Purpose of the Study:

• To discover and characterize a novel small molecule inhibitor targeting multiple kinases.
• To evaluate the safety and efficacy of this inhibitor in preclinical models of neuroblastoma.

Main Methods:

• Rational pharmacophore merging and X-ray crystallography were used to design LCI133.
• Kinome profiling (scanMAX assay) assessed LCI133 selectivity against 468 kinases.
• Pharmacokinetic studies in mice and in vitro/in vivo efficacy studies in neuroblastoma models were performed.

Main Results:

• LCI133 is a potent nanomolar inhibitor of CDK4/6/9 and AURKA/B, with high selectivity.
• Pharmacokinetic studies showed good systemic exposure in mice (AUC: 7812 ng × h/mL, Cmax: 3305 ng/mL).
• LCI133 demonstrated nanomolar sensitivity in neuroblastoma cells and potent antitumor effects in vivo without overt toxicity, improving survival rates.

Conclusions:

• LCI133 represents a first-in-class multi-target inhibitor with potential for treating high-risk cancers like neuroblastoma.
• The multi-targeting strategy may offer improved safety and efficacy by circumventing resistance mechanisms.